Low Float (Nasdaq: MDCX) Tops Monday’s Biotech Watchlist (5 Potential Catalysts On Radar) *Click Here To Get Our Alerts Faster Via SMS* December 14thGreetings Readers, In the fast-evolving world of life sciences, this company stands out for its bold approach to closing major treatment gaps. Its subsidiary is developing a dissolvable microneedle patch designed to deliver chemotherapy directly into tumors, a promising new method for treating basal cell carcinoma. Ongoing clinical trials in both the U.S. and UAE reflect the company’s commitment to advancing cancer care that avoids surgery and minimizes discomfort. Recent strategic moves—such as acquiring a UK biotech focused on prostate cancer—have reinforced its competitive edge. Driven by speed, precision, and data-informed development, the company is reshaping expectations in both human health. And with a float of fewer than 8Mn, a recently completed, game-changing acquisition, and multiple analyst targets suggesting massive upside potential, this Nasdaq profile has just overtaken my watchlist once again. Take a moment to consider this idea for your radar: *Medicus Pharma Ltd. (Nasdaq: MDCX)* Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. The company is actively engaged in multiple countries, spread over three continents. And based on several potential catalysts, (Nasdaq: MDCX) has pushed its way to the top of my watchlist. Take a look: No. 1 – A Low Float Could Create The Environment For Heightened Volatility. No. 2 – Medicus Pharma Files Key Application Toward Accelerated Skin Cancer Therapy Approval. No. 3 – An Average Of 6 Analyst Targets Suggest Major Upside Potential (Triple-Digit And More!). No. 4 – Medicus Pharma Expands Global Clinical Footprint With UK Study Approval Milestone. No. 5 – MDCX Leads Innovative Collaboration Advancing Compassionate SKINJECT Access Globally. But more on those in a second… Company Breakdown – Medicus Pharma Ltd. (Nasdaq: MDCX) Medicus Pharma Ltd. specializes in rapidly moving forward the clinical development of cutting-edge therapeutic solutions within the biotech and life sciences sector.

About SkinJect – Medicus Pharma’s (Nasdaq: MDCX) Wholly Owned Subsidiary A novel non-invasive regimen to treat skin cancer; especially Basal Cell Carcinoma. SkinJect Inc. is a development stage biotechnology life sciences company focused on commercializing novel treatment for non-melanoma skin cancer, especially basal cell carcinoma, using a patented dissolvable doxorubicincontaining microneedle arrays (D-MNA). D-MNA delivers the chemotherapeutic agent transdermally at the site of the lesion to eradicate tumor cells. The relevant US Patents were granted to University of Pittsburgh and Carnegie Mellon University in 2018.

SkinJect Inc. secured exclusive worldwide development and commercialization rights from University of Pittsburgh and Carnegie Mellon University in April 2016. The company attempts to provide an alternative to an invasive, painful, but effective treatment commonly called Mohs Surgery, by providing an efficacious, painless and easy to administer treatment in an office setting. SkinJect Inc. has completed a Phase I study in March 2021 for participants with superficial and nodular Basal Cell Carcinoma (BCC). In January 2024 a Phase 2 IND clinical protocol was submitted to the FDA for a randomized, controlled, double-blind, multicenter study that is expected to randomize up to 60 patients. Patient recruitment began in August 2024 in 9 sites across the United States. A positively trending interim analysis in March 2025 showed more than 60% complete clinical response. In April 2025, IRB approved an increase in the number of patients from 60 to 90. SkinJect Clinical Development Outlook

The SkinJect Value Proposition 1. Innovative Microneedle Patch Technology: The company aims to provide an alternative to an invasive, painful, but effective treatment commonly called Mohs Surgery, by providing an efficacious, painless and easy to administer treatment in an office setting.Patented technology for non-invasively treating skin cancer using cellulose-based microneedles to deliver cancer drugs directly to the tumor siteExclusive worldwide development and commercialization rights from University of Pittsburgh and Carnegie Mellon University in April 2016. 2. Market Potential: BCC is the most common and fastest-growing cancer globally.>US$15Bn market for skin cancer treatments in North America by 2030. (1)Potential for further market expansion and penetration by SkinJect’s novel treatment approach. 3. Positive Clinical Trial Results: Phase 1 trial completed March 2021, demonstrating safety and tolerability.In Q1 2024 a Phase 2 IND clinical protocol was submitted to the FDA for a randomized, controlled, double-blind, multicenter study.In Q3 2024 Phase 2 enrollment began.In Q1 2025 conducted interim analysis after 50% patient recruitment.In Q2 2025, IRB approved to increase number of patients from 60 to 90. 4. Seasoned Leadership and Board: Management team with public company experience.Board includes industry veterans and experts in oncology and drug development. About Recent Acquisition: Antev Ltd. Antev Ltd. (“Antev”) is a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, a potentially first in market product for high-risk prostate cancer patients and patients with first acute urinary retention (AUR) episodes due to enlarged prostate. Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. Teverelix: A Next-Gen GnRH Antagonist Teverelix is being developed to compete with or improve upon current GnRH antagonists like Degarelix and Relugolix as well as agonists. What sets Teverelix apart is the potential for: Rapid onset of testosterone suppression and prostate shrinkage Avoidance of testosterone flare versus agonists A longer-acting injection schedule (possibly every 6 weeks) Potential for subcutaneous and intra-muscular delivery without daily dosing (vs. Relugolix’s daily oral use) Due to superior formulation, ISRs potentially significantly milder compared to Degarelix What’s Next for Teverelix?

Grab Key Sources: MDCX Presentation. MDCX Website.—– And as I mentioned previously, (Nasdaq: MDCX) has several potential catalysts that could generate breakout buzz. Check them out: No. 1 MDCX Potential Catalyst – A Low Float Could Create The Environment For Heightened Volatility. According to info from the Finviz website, MDCX has a fairly low float. The website reports this profile to have roughly 7.58Mn shares in its float. Why is that important? It’s important on one crucial level. Volatility potential. If positive company news appears towards the end of 2025, could it provide a breakout spark when paired with the volatility potential of this low float?—– No. 2 MDCX Potential Catalyst – Medicus Pharma Files Key Application Toward Accelerated Skin Cancer Therapy Approval. Medicus Pharma Ltd. Announces Filing of FDA Commissioner’s National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin SKNJCT-003 Doxorubicin containing Microneedle Array (D-MNA) clinical development program to non-invasively treat BCC aligns with national priorities of public health impact, unmet medical need, access, affordability, domestic manufacturing and rare-disease alignment PHILADELPHIA, Nov. 17, 2025 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it has submitted an FDA Commissioner’s national priority voucher (CNPV) application on behalf of Skinject (SKNJCT-003) evaluating Doxorubicin Microneedle Array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin. The submission includes a complete Statement of Interest outlining SkinJect’s alignment with FDA national priorities in cancer care access, affordability, and rare-disease needs. On June 17, 2025, FDA Commissioner Marty Makary, MD, MPH announced a new approval pathway, the Commissioner’s National Priority Voucher (CPNV) for approval of drugs to enhance the health interests of Americans. Previously, on May 25 he identified psych-e-delic drugs for treatment of suicidal depression and PTSD as a national priority. The new voucher may be redeemed by drug developers to participate in a commissioner-led program that shortens its review time from approximately 10-12 months to 1-2 months following a sponsor’s final drug application submission. The new CNPV process convenes experts from FDA offices for a team-based review rather than using the standard review system of a drug application being sent to numerous FDA offices. The FDA plans, in the first year of the program, to give a limited number of vouchers to companies aligned with U.S. national priorities. In addition to receiving the benefits of this program, the agency may also grant an accelerated approval, if the product for which the voucher is used meets the applicable legal requirements for accelerated approval. The FDA Commissioner will use specific criteria to make the vouchers available to companies that are aligned with the national health priorities of addressing a health crisis in the U.S., delivering more innovative cures for the American people, addressing unmet public health needs, and increasing domestic drug manufacturing as a national security issue. The Company believes it meets each of the above criteria and seeks inclusion in the CNPV Pilot Program to enable enhanced FDA collaboration and expedited review, accelerating access to a U.S.-developed, cost-effective, cancer therapy that supports national goals of improving access, safety, and quality of care and providing access to Gorlin Syndrome patients that have no available treatment. “We believe that SkinJect’s D-MNA is uniquely positioned to expand access to effective non-melanoma skin cancer treatment, especially BCC, while dramatically reducing healthcare costs and surgical dependence,” stated Dr. Raza Bokhari, Medicus’s Executive Chairman & CEO. “Our CNPV submission emphasizes not only SkinJect’s broad public-health value but also its profound potential impact on patients with Gorlin syndrome, who often endure hundreds of surgeries in their lifetime. We believe SkinJect represents the type of U.S.-developed, patient-centered innovation that the FDA’s CNPV program is designed to accelerate; a non-surgical, low-cost innovation for America’s most common cancer.” … Read the full article here.—– No. 3 MDCX Potential Catalyst – An Average Of 6 Analyst Targets Suggest Major Upside Potential (Triple-Digit And More!). Check out what MarketBeat is reporting:

As of Friday’s close, MDCX had 6 analyst targets pointing to a significant amount of upside potential. In fact, with an average target of $23.50, MDCX could have over 1,000% potential upside from its closing valuation on Friday the 12th. MarketBeat reports further that Jason Kolbert of D. Boral Capital has given MDCX a $27 target representing a potential upside over 1,200% from Friday’s close. Additionally, the website shares Jason McCarthy of Maxim Group has provided a $20 target suggesting 900+% potential upside from Friday’s close. Could (Nasdaq: MDCX) be undervalued from current chart levels?—– No. 4 MDCX Potential Catalyst – Medicus Pharma Expands Global Clinical Footprint With UK Study Approval Milestone. Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin PHILADELPHIA, PA / ACCESS Newswire / November 13, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it has received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study (SKNJCT-003) evaluating Doxorubicin Microneedle Array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin. The phase 2 clinical study (SKNJCT-003) which is currently underway in nine (9) clinical sites in the United States can now expand into additional sites in the United Kingdom. The approvals were issued by the Medicines and Healthcare products Regulatory Agency (MHRA), the Health Research Authority (HRA) and the Wales Research Ethics Committee (WREC). The MHRA approval followed a comprehensive scientific review of the Investigational Medicinal Product Dossier (IMPD) and protocol. The WREC issued a favorable ethical opinion, and the HRA granted study wide governance approval, confirming compliance with U.K. Good Clinical Practice and National Health Service (NHS) capacity and capability standards. “The United Kingdom regulatory and ethical approval is another major step forward in establishing a global footprint of our novel, non-invasive treatment for BCC of the skin, which we believe represents more than $2Bn in potential market opp.,” stated Dr. Raza Bokhari, Medicus’s Executive Chairman & CEO. “With clinical development programs now active across the United States, Europe, and the Middle East, we are enhancing global patient recruitment and clinical dataset which, among other things, would assist us in designing a robust pivotal program.“ … Read the full article here.—– No. 5 MDCX Potential Catalyst – MDCX Leads Innovative Collaboration Advancing Compassionate SKINJECT Access Globally. Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000 people worldwide that can develop 500-1000 Basal Cell Carcinoma (BCC) lesions over lifetime PHILADELPHIA, Oct. 29, 2025 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SKINJECT™, the Company’s investigational doxorubicin containing microneedle arrays (D-MNA) for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome. Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the Food and Drug Administration (FDA) to allow patients with multiple, recurrent, or inoperable basal cell carcinomas (BCCs) to access SKINJECT™ under physician-supervised treatment protocols. The initiative aims to establish a framework for expanded access while collecting valuable real-world safety and tolerability data to inform future regulatory filings. It will also more tightly integrate patient community-led insights and data into the design, monitoring, and long-term development of SKINJECT™ in this rare disease population. SKINJECT™, is a novel localized immunogenic investigational precision therapy focused on non-melanoma skin diseases, especially basal cell carcinoma (BCC) of the skin. Gorlin Syndrome is an inherited condition affecting approximately 1 in 31,000 people worldwide. Patients can develop hundreds to over one thousand basal cell carcinomas (BCCs) over their lifetime, often beginning in early childhood. The disease imposes not only a medical but also a physical, emotional and economic toll, requiring frequent scar producing surgeries, topical treatments and lifelong dermatologic care. “Patients with Gorlin Syndrome endure a lifelong burden of recurring skin cancers that often require repeated surgeries and disfiguring treatments,” said Dr. Raza Bokhari, Executive Chairman & CEO of Medicus. “By working together with the Gorlin Syndrome Alliance, we hope to unite clinical science, regulatory leadership and advocacy to deliver hope for individuals facing lifelong burdens of Gorlin Syndrome, reinforcing our mission to deliver targeted innovation where medical need is greatest.” … Read the full article here.—– (Nasdaq: MDCX) Recap – These 5 Potential Breakout Catalysts Lead The Way No. 1 – A Low Float Could Create The Environment For Heightened Volatility. No. 2 – Medicus Pharma Files Key Application Toward Accelerated Skin Cancer Therapy Approval. No. 3 – An Average Of 6 Analyst Targets Suggest Major Upside Potential (Triple-Digit And More!). No. 4 – Medicus Pharma Expands Global Clinical Footprint With UK Study Approval Milestone. No. 5 – MDCX Leads Innovative Collaboration Advancing Compassionate SKINJECT Access Globally.—– Medicus Pharma Ltd. (Nasdaq: MDCX) has taken over controls of Monday’s radar. Updates will be following shortly. Keep your eyes peeled. Sincerely,Kai ParkerStockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 12/14/2025 and ending on 12/15/2025 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD (“Funds”). To date, including under the previously described agreement, SWN Media LLC has been paid one hundred seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (MDCX:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/mdcx-yiiay/#details